Moreover, the failure of PPI therapy may increase the psychological burden, establishing a vicious cycle.38 We found that Tojapride is clinically efficacious against GERD, fulfils unmet needs for PPI therapy and can inhibit CaSR‐mediated NLRP3 inflammasome activation. This evidence concerns the gene NLRP3 and gastroesophageal reflux disease.